Recent

% | $
Quotes you view appear here for quick access.

Staples, Inc. Message Board

gswkool 80 posts  |  Last Activity: Mar 9, 2015 4:18 PM Member since: Jan 2, 2012
  • Reply to

    S-8 Form

    by toxlcdumper1 Jan 1, 2015 7:58 PM
    gswkool gswkool Jan 2, 2015 11:25 AM Flag

    yes it seems like we're positioned for blrx to have a good year. expanded pipeline, nvs deal, and hopefully more news on clinical front.....past poor performance does not guarantee future poor performance....glta

  • gswkool gswkool Jan 1, 2015 11:25 AM Flag

    sincerely, -why are you posting about vicl on isis board? to attract attention to vicl? vicl melanoma drug, which was furthest along in pipeline, failed. their stock crashed. no success with their platform to date. i lost money when they crashed. more than made it back on isis among others. after taking a tax loss on vicl i did buy shares again for their HSV drug. i didn;t buy much - success and their stock will sky rocket. but its a #$%$shoot. isis on the other hand is no #$%$ shoot. the two aren't mutually exclusive. one can invest in both -i invested in vicl small amount as a complete gamble with big payoff and more in isis because i know it has good future......glta

  • Reply to

    Will stick with position here thru 2015.

    by tene1961 Dec 30, 2014 7:11 PM
    gswkool gswkool Dec 31, 2014 12:03 PM Flag

    well, Hanna- as to who wouldn't sell - you'd be surprised. to me, if it's very obvious either way as per your description, that will do. if it's a difficult call we know they can't do Phase III on their own - a good partner would indicate confidence in results - from some of my other investments it can take up to 6 months or longer to work out partnership details and contracts. that's it in a nutshell to me. if you like small stocks check out BLRX - i've been accumulating there. it has interesting business model and recently when NVS signed on and bought 10% the stock hardly budged. undervalued imo.........merry xmas & happy new year.....

  • gswkool gswkool Dec 31, 2014 10:43 AM Flag

    interesting company and good technology. clearly a future winner. it's hard to figure out what it should be worth today though, and how fast it will grow. projected sales next year is $12M. I don't know who pulled that number out of their hat. If that is so, -that's a small number for this market cap, as net profit will be smaller to maybe even negative. i'm kinda on the sidelines with this one. i'm certainly gonna continue to follow the story here and just hope i don't miss the boat...

  • gswkool gswkool Dec 31, 2014 10:34 AM Flag

    last day for tax loss selling.......... i've seen companies where key mgmt did not hold shares and the company did quite well. and i've seen the reverse. if you look at it from their perspective, they win either way. if the company does well, they will issue more stock options and capitilize. so they don't have to hold onto shares to do well. i do like to see an investment in the company by mgmt so i know what you're saying - i just wouldn't tie it directly to stock performance in all cases.........

  • Reply to

    Let's Talk Today

    by stockaroo87 Dec 30, 2014 5:36 PM
    gswkool gswkool Dec 31, 2014 10:26 AM Flag

    you stated you bought shares for as little #$%$25 -how is that not performance? you're basically full of it -please don't bother to waste anyones time with your posts - find a clueless board to post on -there are a lot of them out there -

  • Reply to

    Let's Talk Today

    by stockaroo87 Dec 30, 2014 5:36 PM
    gswkool gswkool Dec 31, 2014 10:18 AM Flag

    if you've paid as little as .25 then how have you suffered? you're basically full of it. if you don't know how to invest and when to buy -then instead of complaining maybe you should find something more constructive to do with your time......

  • Reply to

    Will stick with position here thru 2015.

    by tene1961 Dec 30, 2014 7:11 PM
    gswkool gswkool Dec 31, 2014 10:11 AM Flag

    it's not just about the individual drug -it's about the platform. so to me i'm watching their most advanced candidate rxi 109. if it shows efficacy that bodes well for the rest of the platform. that would be really big news. if it does not show efficacy, then i will unload my shares promptly. thats my view imho...

  • Reply to

    Let's Talk Today

    by stockaroo87 Dec 30, 2014 5:36 PM
    gswkool gswkool Dec 30, 2014 7:11 PM Flag

    what's wrong with $4.12? I paid $1.26 .......

  • Reply to

    i would expect a small jump in stock price

    by gswkool Dec 29, 2014 4:15 PM
    gswkool gswkool Dec 30, 2014 7:09 PM Flag

    we're powering up today - up a power penny......go BLRX!

  • gswkool gswkool Dec 30, 2014 3:02 PM Flag

    Are they serving steak and lobster? Or maybe a grab bag? They need something catchy -otherwise, they may have trouble getting people to attend..

  • gswkool gswkool Dec 29, 2014 5:54 PM Flag

    it's never easy assessing value. just keep in mind a few things. first, as they get approvals for their technology the costs of development and running clinical trials will drop off. second, try to look at it from an acquirers' point of view. what would a company pay to buy out CERS? The other company will most likely have plenty of synergies, so the overhead reported by CERS will be easily absorbed. third, with CERS you need to look at size of the addressable market ahead of them and whether there will be demand for their products. fourth, look at value of technology itself, the patents, and the cost and time that went into development. I can go on. You get the picture. In the end, the price is what the market will bear at that moment. Today it's $500M.....

  • at beginning of 2015 once tax loss sellers are flushed out. I believe BLRX is also presenting at a conference in January -with the NVS partnership they may garner a little more attention {hopefully not just wishful thinking}....glta

  • Reply to

    Near term outlook for pSivida

    by godwintom Dec 26, 2014 1:46 PM
    gswkool gswkool Dec 29, 2014 11:57 AM Flag

    Hmm - I believe the Lluvien launch in US is January? So I would expect sales to be a small blip in Feb quarterly report. IMHO need more time to see how it goes. But I do understand your sentiments and concerns...GSW

  • Reply to

    Mark Fisher on Fast Money

    by foogie88 Dec 22, 2014 12:16 PM
    gswkool gswkool Dec 28, 2014 1:24 AM Flag

    i don't trust a lot of these guys that go on tv spouting their opinions. how do you know what they say and what they do are not two different things? if he likes it so much, -let him buy it. for me way too early -SU is a good company in a bad oil market. until things play out more and price of oil stabilizes, no one knows where we are really at -my guess is as long as Saudis commit to keep pumping, price will remain low and price of oil companies will move lower as earnings adjustments are made to down side. watch all the 1Q earnings warnings in the sector -they're coming......

  • Reply to

    Near term outlook for pSivida

    by godwintom Dec 26, 2014 1:46 PM
    gswkool gswkool Dec 28, 2014 1:14 AM Flag

    I've missed out on some good opportunities in the past because I liked the company but thought I could wait for a better price. I wish you good luck with that strategy. What would the price have to be for you to purchase shares? Anyhow, I think the price at this point is very reasonable. I'm not particularly worried about PSDV. I hate to see other investors miss the boat, esp. if they have held the shares for some time in the past. I've been down that road and when it happens it hurts......glta

  • Reply to

    Okay. Now it's time to cut some deals.

    by helpme_hanna Dec 26, 2014 11:00 AM
    gswkool gswkool Dec 27, 2014 1:15 PM Flag

    They need to prove their technology works before there will be any deal. RXI-109 is the only candidate in a position to garner attention. The other candidates are pre-clinical. You still need to wait for positive results for RXI-109. I haven't seen anything substantive enough to warrant a partnership......yet. So you may be disappointed in near term. I do look at a bunch of factors before investing. In this case it only warranted a small share purchase. Wtih small, speculative companies such as RXII, I adopt a "show me" attitude. I will reward progress with addiitonal purchases and dollar cost average over time. Fail me -give me bad news - and I will most likely sell some or all of my position. That strategy has worked out quite well for me. I do not get emotionally attached to my investments. You seem a little naive about how things work in biotech land and by the number of your posts you seem quite attached to this stock. One should always remain detached and diversify, esp. when investing in biotech land.........glta

  • Reply to

    Near term outlook for pSivida

    by godwintom Dec 26, 2014 1:46 PM
    gswkool gswkool Dec 27, 2014 12:44 PM Flag

    Agree on forgetting about buyout -too early in the game. As for 2015, -there can be other catalysts. Early 2015 they expect to complete PIII Uveitis enrollment. They also expect to meet with FDA to confirm strategy. Confirmation of one trial only for Uveitis is important. PSDV also working on additional collaborations. Possible additional clinical progress for vein occlusion and dry AMD indications. Vein occlusion is 200,000 patient market. Dry AMD is huge market. For Tethadur an IND may come late in the year if at all. There may still be news on partnership front though. Expect another busy year for PSDV. I'm not a day trader. IMHO long term this company has big potential. My return on share purshases has been close to 100% since I began purchases two years ago. How can I be diappointed with that? Investing requires good timing but also a lot of patience, esp. with biotechs.......GLTA

  • Reply to

    Another year no approval.

    by cmhe Dec 23, 2014 2:55 AM
    gswkool gswkool Dec 27, 2014 11:31 AM Flag

    the teva patent will expire ......looks like before the courts act on their decision.........teva will have had time to switch patients to the new formulation - however judging by recent action of ESRX PBM, when the genreic comes out will PBMs find enough of a benefit to allow patients to continue on TEVA's new formulation or will they push patients to go generic? It's possible the latter will happen. So Teva looks to be winning the game now, -but it's certainly not over. I'm holding onto my stock -I got it at a good price anyway. IMHO this stock will be trading at higher price by end of 2015....glta

  • Reply to

    Okay. Now it's time to cut some deals.

    by helpme_hanna Dec 26, 2014 11:00 AM
    gswkool gswkool Dec 27, 2014 11:24 AM Flag

    First they need some positive clinical results. What kind of deal are you thinking of? Unfortunately they are not far enough along, -which is why they most likey entered into the deal with Hapten. Having two phase II compunds is better than having one -they are hedging their bets. At what cost? I have small amount of stock here -i'm not going to over analyze - time will tell if they did right thing for shareholders. Companies can have early stage pipelines and larger market caps depending on their pedigree i.e. their standing in scientific community. The low valuation to me indicates either they are not getting recognition they deserve or they are seconds rate. Again, time will tell.....

SPLS
16.02-0.52(-3.17%)Mar 26 4:00 PMEDT